Richard Francis Riedel, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Dept of Medicine, 25179 Morris Bldg, Durham, NC 27710
Phone (919) 681-8031
Email address richard.riedel@duke.edu

Novel therapies for soft tissue and bone sarcomas

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 2005 - 2007
  • Fellow in Hematology-Oncology, Medicine, Duke University, 2003 - 2004
  • Resident in Medicine, Medicine, Duke University, 2000 - 2003
  • M.D., Thomas Jefferson University, 2000

Publications

Riedel, Richard, Sebastian Michels, Carina Heydt, Janna Siemanowski, Carsten Kobe, Anne Bunck, Stephan Schäfer, et al. “Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma..” Lung Cancer 133 (July 2019): 20–22. https://doi.org/10.1016/j.lungcan.2019.05.006.

PMID
31200822
Full Text

Davis, Lara E., Vanessa Bolejack, Christopher W. Ryan, Kristen N. Ganjoo, Elizabeth T. Loggers, Sant Chawla, Mark Agulnik, et al. “Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma..” J Clin Oncol 37, no. 16 (June 1, 2019): 1424–31. https://doi.org/10.1200/JCO.18.02374.

PMID
31013172
Full Text

Ray, Emily M., Richard F. Riedel, Thomas W. LeBlanc, Christel N. Rushing, and Anthony N. Galanos. “Assessing the Impact of a Novel Integrated Palliative Care and Medical Oncology Inpatient Service on Health Care Utilization before Hospice Enrollment..” J Palliat Med 22, no. 4 (April 2019): 420–23. https://doi.org/10.1089/jpm.2018.0235.

PMID
30394821
Full Text

Schwartz, Abby J., Richard F. Riedel, Thomas W. LeBlanc, Devi Desai, Carol Jenkins, Ellen Mahoney, Janice Humphreys, and Cristina C. Hendrix. “The experiences of older caregivers of cancer patients following hospital discharge..” Support Care Cancer 27, no. 2 (February 2019): 609–16. https://doi.org/10.1007/s00520-018-4355-2.

PMID
30027328
Full Text

Riedel, Richard F. “Anti-angiogenic therapy for malignant solitary fibrous tumour: validation through collaboration..” The Lancet. Oncology 20, no. 1 (January 2019): 14–15. https://doi.org/10.1016/s1470-2045(18)30745-9.

PMID
30578024
Full Text

Gounder, Mrinal M., Michelle R. Mahoney, Brian A. Van Tine, Vinod Ravi, Steven Attia, Hari A. Deshpande, Abha A. Gupta, et al. “Sorafenib for Advanced and Refractory Desmoid Tumors..” The New England Journal of Medicine 379, no. 25 (December 2018): 2417–28. https://doi.org/10.1056/nejmoa1805052.

PMID
30575484
Full Text

Riedel, Richard F., Robin L. Jones, Antoine Italiano, Chet Bohac, Juliette C. Thompson, Kerstin Mueller, Zaeem Khan, Seth M. Pollack, and Brian A. Van Tine. “Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review..” Cancers (Basel) 10, no. 11 (November 1, 2018). https://doi.org/10.3390/cancers10110417.

PMID
30388821
Full Text

Wisdom, Amy J., Yvonne M. Mowery, Richard F. Riedel, and David G. Kirsch. “Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma..” Cancer 124, no. 19 (October 1, 2018): 3819–29. https://doi.org/10.1002/cncr.31517.

PMID
29723407
Full Text

Vlahovic, Gordana, Kellen L. Meadows, Ace J. Hatch, Jingquan Jia, Andrew B. Nixon, Hope E. Uronis, Michael A. Morse, et al. “A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer..” Oncologist 23, no. 7 (July 2018): 782–90. https://doi.org/10.1634/theoncologist.2016-0377.

PMID
29572245
Full Text

Gounder, Mrinal M., Neeta Somaiah, Steven Attia, Sant P. Chawla, Victor Manuel Villalobos, Bartosz Chmielowski, Melissa Amber Burgess, et al. “Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study..” In Journal of Clinical Oncology, 36:11512–11512. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.11512.

Full Text

Pages